Home
Astrazeneca Pharma India Share Price Target 2025, 2026, 2027 to 2030

Astrazeneca Pharma India Share Price Target 2025, 2026, 2027 to 2030

Price Target March 15, 2025 0
Tweet
Share
Pin
Share
0 Shares

AstraZeneca Pharma India Ltd, a prominent biopharmaceutical company in India and a subsidiary of AstraZeneca Plc, headquartered in Cambridge, UK, has been at the forefront of advancing healthcare since its establishment in 1979. Headquartered in Bengaluru, Karnataka, the company is dedicated to leveraging science and innovation to deliver transformative medicines that enhance the health and lives of people across India. AstraZeneca Pharma India Ltd operates across key therapeutic areas, including oncology, cardiovascular, renal, metabolic diseases, respiratory, and immunology, addressing some of the most pressing medical challenges of our time. Renowned for its strong focus on research and development, the company strives to meet unmet medical needs by introducing cutting-edge therapies to the market. Beyond its core business of manufacturing, distributing, and marketing pharmaceutical products, AstraZeneca Pharma India actively collaborates with healthcare providers, government bodies, and patient advocacy groups to improve access to treatments. It also undertakes various initiatives to bolster patient education and strengthen healthcare infrastructure, underscoring its commitment to advancing the overall healthcare ecosystem in India.

Shareholdings Patterns of Astrazeneca Pharma India

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters +75.00%75.00%75.00%75.00%75.00%
FIIs +2.66%2.73%2.79%2.90%2.92%
DIIs +2.76%3.77%4.99%5.08%5.21%
Public +19.57%18.50%17.21%17.02%16.85%
No. of Shareholders29,03229,41827,16927,61527,322

The shareholding pattern of AstraZeneca Pharma India Ltd from December 2023 to December 2024 reflects stability and evolving investor confidence. Promoters maintained a consistent 75% stake throughout the period, showcasing their unwavering commitment. Foreign Institutional Investors (FIIs) gradually increased their holdings from 2.66% to 2.92%, while Domestic Institutional Investors (DIIs) showed significant growth, rising from 2.76% to 5.21%, highlighting strong domestic and international interest in the company. Public shareholding declined from 19.57% to 16.85%, indicating a shift towards institutional ownership. The number of shareholders also saw a slight consolidation, reducing from 29,032 to 27,322, suggesting a more concentrated and potentially strategic shareholder base. These trends underscore AstraZeneca Pharma India Ltd’s appeal as a stable and attractive investment option for institutional stakeholders.

Latest News on AstraZeneca Pharma India

AstraZeneca Pharma India Ltd has recently achieved a significant milestone by securing approval from India’s drug regulatory authority to import and sell sodium zirconium cyclosilicate powder, marketed under the brand name Lokelma. This innovative medication is specifically designed to treat hyperkalaemia, a medical condition marked by abnormally high potassium levels in the blood, which can lead to serious cardiovascular and renal complications if left untreated. Lokelma represents a vital addition to AstraZeneca’s portfolio, addressing a critical therapeutic need in the management of electrolyte imbalances. This approval underscores the company’s commitment to bringing advanced, science-driven treatments to the Indian market, enhancing its contribution to improving patient outcomes in the region.

How to Purchase AstraZeneca Pharma India Shares in India?

Below are the trading platforms that you can use to purchase AstraZeneca Pharma India shares:

➤ Zerodha

➤ Upstox

➤ Groww

➤ AngelOne

➤ ICICIDirect

AstraZeneca Pharma India Share Price Target 2025, 2026 to 2030

AstraZeneca Pharma India Share Price Target 2025

WhenMaximum PriceMinimum Price
April 20258,117.776,244.44
May 20257,881.336,062.56
June 20258,235.996,335.38
July 20258,074.506,211.15
August 20258,324.236,403.25
September 20258,424.126,480.09
October 20258,643.146,648.57
November 20258,859.226,814.79
December 20259,257.897,121.45

As we move through 2025, AstraZeneca Pharma India’s share price is expected to show significant fluctuations. In April, the maximum share price may reach ₹8,117.77, while the minimum share price could be around ₹6,244.44. By December, the maximum share price is projected to rise to ₹9,257.89, with the minimum share price anticipated at ₹7,121.45.

Finances rule

AstraZeneca Pharma India Share Price Prediction 2026

WhenMaximum PriceMinimum Price
January 20269,535.627,335.10
February 20269,297.237,151.72
March 20269,483.187,294.75
April 20269,676.717,443.62
May 20269,580.907,369.93
June 20269,820.437,554.17
July 20269,627.877,406.05
August 20269,925.647,635.11
September 202610,124.157,787.81
October 202610,387.387,990.29
November 202610,647.068,190.05
December 202610,913.248,394.80

In 2026, AstraZeneca Pharma India’s share price is projected to exhibit a consistent upward trajectory. In January, the maximum share price is expected to reach ₹9,535.62, with the minimum price around ₹7,335.10. By December, the share price is anticipated to rise further, with a maximum of ₹10,913.24 and a minimum of ₹8,394.80.

AstraZeneca Pharma India Share Price Target 2027

WhenMaximum PriceMinimum Price
January 202711,022.378,478.75
February 202711,305.008,696.15
March 202711,745.899,035.30
April 202711,515.588,858.14
May 202711,180.178,600.13
June 202711,683.288,987.14
July 202711,454.208,810.92
August 202711,808.459,083.42
September 202712,221.759,401.34
October 202712,539.519,645.78
November 202712,853.009,886.92
December 202713,174.3310,134.10

AstraZeneca Pharma India Share Price Prediction 2028

WhenMaximum PriceMinimum Price
January 202813,437.8110,336.78
February 202813,782.3710,601.82
March 202814,319.8811,015.30
April 202814,039.1010,799.31
May 202813,630.2010,484.77
June 202814,243.5510,956.58
July 202813,964.2710,741.75
August 202814,396.1511,073.96
September 202814,900.0211,461.55
October 202815,287.4211,759.55
November 202815,669.6112,053.54
December 202816,061.3512,354.88

AstraZeneca Pharma India Share Price Target 2029

WhenMaximum PriceMinimum Price
January 202916,382.5712,601.98
February 202916,802.6412,925.11
March 202917,457.9413,429.19
April 202917,115.6313,165.87
May 202916,617.1212,782.40
June 202917,364.8913,357.60
July 202917,024.4013,095.69
August 202917,550.9313,500.71
September 202918,165.2113,973.24
October 202918,637.5014,336.54
November 202919,103.4414,694.95
December 202919,581.0315,062.33

AstraZeneca Pharma India Share Price Target 2030

WhenMaximum PriceMinimum Price
January 203019,972.6515,363.57
February 203020,484.7715,757.51
March 203021,283.6716,372.06
April 203020,866.3516,051.04
May 203020,258.5915,583.53
June 203021,170.2216,284.79
July 203020,755.1215,965.48
August 203021,397.0316,459.26
September 203022,145.9317,035.33
October 203022,721.7217,478.25
November 203023,289.7717,915.20
December 203023,872.0118,363.08

As we progress through 2030, AstraZeneca Pharma India’s share price is anticipated to show substantial growth. In January, the maximum share price is expected to reach ₹19,972.65, with the minimum price around ₹15,363.57. By December, the share price is projected to climb significantly, with a maximum of ₹23,872.01 and a minimum of ₹18,363.08. These figures highlight AstraZeneca Pharma India’s potential to sustain strong market performance throughout the year.

Financial Condition of AstraZeneca Pharma India

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales +8328148061,0031,2961,619
Expenses +7116787198381,1111,402
Operating Profit12113586165184217
OPM %15%17%11%16%14%13%
Other Income +131315-1451-58
Interest111111
Depreciation192017161526
Profit before tax11412783134220132
Tax %37%27%26%26%26%
Net Profit +7293629916297
EPS in Rs28.8837.3224.6439.7264.638.78
Dividend Payout %3%5%41%40%37%

AstraZeneca Pharma India has demonstrated a strong financial performance from March 2020 to March 2024, with significant growth across key metrics. The company’s sales revenue has risen steadily from ₹832 crore in March 2020 to ₹1,296 crore in March 2024, with a trailing twelve-month (TTM) figure of ₹1,619 crore. This strong growth highlights AstraZeneca Pharma India’s expanding market presence and increasing demand for its pharmaceutical products. Concurrently, expenses have increased from ₹711 crore in March 2020 to ₹1,111 crore in March 2024, reflecting investments to support this growth trajectory. Despite fluctuations, the operating profit has also grown from ₹121 crore to ₹184 crore over the same period, supported by an efficient expense management strategy.

The company’s profitability metrics indicate resilience despite challenges. The OPM (Operating Profit Margin) has varied between 11% and 17% over the years, settling at 14% in March 2024. Other income showed variability, with a significant peak at ₹51 crore in March 2024, though it reflected a negative value in the TTM due to specific adjustments. Profit before tax saw a consistent increase, rising from ₹114 crore in March 2020 to ₹220 crore in March 2024, showcasing AstraZeneca Pharma India’s robust financial operations. With a stable tax rate of around 26%, the company’s net profit surged from ₹72 crore in March 2020 to ₹162 crore in March 2024, reinforcing its strong performance.

Shareholder returns have also improved significantly, as reflected in the EPS (Earnings Per Share), which rose from ₹28.88 in March 2020 to ₹64.6 in March 2024. The company maintained a prudent dividend payout ratio, peaking at 41% in March 2022 and stabilizing at 37% in March 2024, ensuring a balance between rewarding shareholders and retaining earnings for future growth.

FAQs

What Is the Market Value of AstraZeneca Pharma India?

The market capitalization (Market Cap) of AstraZeneca Pharma India as of 15th March 2025 is ₹19,189 Crores.

What Is the Current Share Price of AstraZeneca Pharma India?

As of 15th March 2025, the current share price of AstraZeneca Pharma India is ₹7,676.

What Is the Stock PE Ratio of AstraZeneca Pharma India?

The stock P/E ratio for AstraZeneca Pharma India is 114.

What is the Share Price target of AstraZeneca Pharma India for 2030

The Share Price target of AstraZeneca Pharma India is expected to reach ₹23,872.01 by the end of 2030.

Also, check other Companies Share Price Targets:

Conclusion

AstraZeneca Pharma India Ltd continues to lead in healthcare innovation, backed by strong financial performance, strategic collaborations, and a commitment to patient-centric solutions. The company recently launched Lokelma, a groundbreaking treatment for hyperkalaemia, further enhancing its diverse portfolio. This addition underscores AstraZeneca’s focus on addressing critical medical challenges in India. With its dedication to advancing therapies across oncology, cardiovascular, and respiratory domains, alongside strategic partnerships and investments in cutting-edge research, AstraZeneca Pharma India Ltd is well-positioned for sustained growth and greater impact in India’s healthcare landscape.

Financesrule telegram

Author: Ashnoor

Related

Leave a Reply